Well-Come to Agent for Change, a blog created by Marly Silverman, to serve as a catalyst for change that is much needed on the issues affecting millions of individuals stricken with neuroendocrineimmune disorders worldwide. Through this blog I want to share ideas, exchange, communicate and find solutions for everyday living. The goal is to pursue quality of life that will make a difference in the lives of individuals with neuroendocrineimmune disorders (NEIDs).

Thursday, December 20, 2012

Llewellyn King's Dec 15, 2012 article on the Stamford Advocate on the FDA approval meeting of Ampligen dated Dec 20, 2012. 

Llewellyn King host and producer of
the "White House Chronicles" on PBS
Llewellyn King, host and producer of the "White House Chronicles" on PBS wrote an article at the Stamford Advocate regarding the FDA potential approval of Ampligen (Hemisphererx Biopharma) during today's FDA Arthritis Committee review of the Hemisphere Biopharma submission to the FDA to approve Ampligen to treat myalgic encephalomyelitis (ME), which is also known in the U.S. as chronic fatigue syndrome (CFS). 

In his article you will find the positions of Drs. Andrea Kogelnick, Dan Peterson, Derek Endler and personal assessments of ME/CFS patients who clearly benefit while on Ampligen and the downward spiral once they are off the drug. 

According to Llewellyn King "When patient activists face the government in various hearings, it is painfully asymmetrical, it seems to me. The sick tell sad stories of suffering, loss of love as well as health, while the government people talk abstractly about patient loads, international disease definitions, allocation of resources and appear self-important rather than appalled at the suffering that passes before them.
The patients turn to the government for recognition, but the government turns them into a statistic."

Read more: http://www.stamfordadvocate.com/local/article/FDA-to-rule-on-Lazarus-drug-4121250.php#ixzz2FbyRM2kQ

No comments: